Ignite Creation Date:
2024-05-05 @ 11:07 AM
Last Modification Date:
2024-10-26 @ 9:05 AM
Study NCT ID:
NCT00005967
Status:
COMPLETED
Last Update Posted:
2013-02-11
First Post:
2000-07-05
Brief Title:
Tipifarnib in Treating Patients With Advanced Hematologic Cancer
Sponsor:
National Cancer Institute NCI
Organization:
National Cancer Institute NCI
Study Overview
Official Title:
A Dose Finding Study of R115777 NSC 702818 in Patients With Advanced Hematologic Malignancies
Status:
COMPLETED
Status Verified Date:
2004-10
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
Randomized phase I trial to study the effectiveness of tipifarnib in treating patients who have advanced hematologic cancer Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die
Detailed Description:
OBJECTIVES
I Determine the relationship between tipifarnib dose and inhibition of farnesylation in malignant cells of patients with advanced hematologic malignancies
II Determine the safety profile of this drug in this patient population III Determine the clinical activity of this drug in these patients
OUTLINE This is a randomized study Patients are randomized to 1 of 4 dose levels
Patients receive oral tipifarnib twice daily for 21 days Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity After 1 course of therapy patients may receive subsequent therapy at the maximum tolerated dose at the investigators discretion
I Determine the relationship between tipifarnib dose and inhibition of farnesylation in malignant cells of patients with advanced hematologic malignancies
II Determine the safety profile of this drug in this patient population III Determine the clinical activity of this drug in these patients
OUTLINE This is a randomized study Patients are randomized to 1 of 4 dose levels
Patients receive oral tipifarnib twice daily for 21 days Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity After 1 course of therapy patients may receive subsequent therapy at the maximum tolerated dose at the investigators discretion
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| CDR0000067950 | REGISTRY | PDQ Physician Data Query | None |
| UCCRC-10294 | None | None | None |
| NCI-42 | None | None | None |